Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nanoviricides Inc (NNVC)

Nanoviricides Inc (NNVC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,882
  • Shares Outstanding, K 21,568
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,470 K
  • EBIT $ -8 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.04

Options Overview Details

View History
  • Implied Volatility 392.45% (+169.73%)
  • Historical Volatility 90.82%
  • IV Percentile 79%
  • IV Rank 23.69%
  • IV High 1,197.14% on 12/15/25
  • IV Low 142.67% on 10/17/25
  • Expected Move (DTE 23) 0.0340 (2.89%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 145
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 3,556
  • Open Int (30-Day) 4,107
  • Expected Range 1.1410 to 1.2090

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.14
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0700 +11.21%
on 12/03/25
1.4900 -20.13%
on 12/09/25
-0.0500 (-4.03%)
since 11/24/25
3-Month
1.0700 +11.21%
on 12/03/25
2.2299 -46.63%
on 11/05/25
-0.2300 (-16.20%)
since 09/24/25
52-Week
0.9400 +26.60%
on 04/09/25
2.2299 -46.63%
on 11/05/25
-0.3200 (-21.19%)
since 12/24/24

Most Recent Stories

More News
This Clinical-Stage Biotech Just Raised $6M to Advance a Drug That Could Address Pandemic Preparedness Gaps

NanoViricides (NNVC), a clinical-stage antiviral developer, strengthened its financial position in late 2025 with $6.1M in new funding as it advances its lead drug NV-387 toward Phase II tria

NNVC : 1.1900 (-0.83%)
2 Small-Cap Biotechs That Could Reward Patient Investors

Two small-cap biotech stocks offer high risk but significant upside for patient investors as they advance early-stage diagnostic and antiviral programs

NNVC : 1.1900 (-0.83%)
MYNZ : 1.1700 (+1.74%)
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development...

NNVC : 1.1900 (-0.83%)
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending...

NNVC : 1.1900 (-0.83%)
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that...

NNVC : 1.1900 (-0.83%)
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement...

NNVC : 1.1900 (-0.83%)
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a single...

NNVC : 1.1900 (-0.83%)
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of NV-387...

NNVC : 1.1900 (-0.83%)
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan

NNVC : 1.1900 (-0.83%)
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that...

NNVC : 1.1900 (-0.83%)

Business Summary

NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development...

See More

Key Turning Points

3rd Resistance Point 1.3167
2nd Resistance Point 1.2933
1st Resistance Point 1.2467
Last Price 1.1900
1st Support Level 1.1767
2nd Support Level 1.1533
3rd Support Level 1.1067

See More

52-Week High 2.2299
Fibonacci 61.8% 1.7372
Fibonacci 50% 1.5849
Fibonacci 38.2% 1.4327
Last Price 1.1900
52-Week Low 0.9400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar